An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
Background: Gene therapies can treat, prevent, or cure a disease by changing the expression of a person’s genes. They are an innovative strategy for treating genetic disorders; however, they are still emerging on the market access and in the healthcare system. Health technology assessment (HTA) agen...
Saved in:
Main Authors: | Michał Pochopień, Ewelina Paterak, Emilie Clay, Justyna Janik, Samuel Aballea, Małgorzata Biernikiewicz, Mondher Toumi |
---|---|
Format: | article |
Language: | EN |
Published: |
Taylor & Francis Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/754b4c674be641ef872d82a64d8b4e17 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
by: Katarzyna Jabłońska, et al.
Published: (2021) -
Problems of Identification and Analysis of Transaction Costs at the Economic Entity Level
by: Herasymenko Tetiana V.
Published: (2021) -
Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers
by: Tingting Qiu, et al.
Published: (2021) -
SEPARATION OF FIXED AND VARIABLE COSTS FROM MIXED COSTS AT A WATER AND SEWERAGE OPERATOR
by: Árpád-Zoltán Fülöp, et al.
Published: (2021) -
Vocational training costs and economic benefits: exploring the interactions
by: Natalia Samoliuk, et al.
Published: (2021)